[
    [
        {
            "time": "2021-11-29",
            "original_text": "凯莱英：拟使用不超12亿元部分闲置募集资金暂补流动资金",
            "features": {
                "keywords": [
                    "凯莱英",
                    "闲置资金",
                    "流动资金"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英：拟使用不超12亿元部分闲置募集资金暂补流动资金",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "39股获买入评级 最新:八方股份",
            "features": {
                "keywords": [
                    "买入评级",
                    "八方股份"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "39股获买入评级 最新:八方股份",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "医药行业周报：OMICRON成热议 CDMO和上游边际改善",
            "features": {
                "keywords": [
                    "医药",
                    "OMICRON",
                    "CDMO",
                    "上游"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：OMICRON成热议 CDMO和上游边际改善",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "南财脱水研报丨奥密克戎对医疗板块影响如何，复盘德尔塔或能参考",
            "features": {
                "keywords": [
                    "奥密克戎",
                    "医疗板块",
                    "德尔塔"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "南财脱水研报丨奥密克戎对医疗板块影响如何，复盘德尔塔或能参考",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "凯莱英赴港IPO：背后那起让高瓴资本很受伤的A股定增",
            "features": {
                "keywords": [
                    "凯莱英",
                    "IPO",
                    "高瓴资本",
                    "定增"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英赴港IPO：背后那起让高瓴资本很受伤的A股定增",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "华软科技：子公司奥得赛化学为凯莱英供应其生产所需的医药中间体",
            "features": {
                "keywords": [
                    "华软科技",
                    "奥得赛化学",
                    "凯莱英",
                    "医药中间体"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华软科技：子公司奥得赛化学为凯莱英供应其生产所需的医药中间体",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "A股异动丨再签超预期大单 凯莱英(002821.SZ)创历史新高",
            "features": {
                "keywords": [
                    "A股",
                    "凯莱英",
                    "大单",
                    "历史新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股异动丨再签超预期大单 凯莱英(002821.SZ)创历史新高",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "凯莱英(002821)：重大合同再添新单 期待业绩强增长",
            "features": {
                "keywords": [
                    "凯莱英",
                    "重大合同",
                    "业绩增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英(002821)：重大合同再添新单 期待业绩强增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "信达证券发布凯莱英研报，公司点评报告：又见超预期大额订单，公司进入发展快车道",
            "features": {
                "keywords": [
                    "信达证券",
                    "凯莱英",
                    "大额订单",
                    "发展快车道"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "信达证券发布凯莱英研报，公司点评报告：又见超预期大额订单，公司进入发展快车道",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-29",
            "original_text": "平安证券维持凯莱英强烈推荐评级：再签大订单，提高未来盈利预期",
            "features": {
                "keywords": [
                    "平安证券",
                    "凯莱英",
                    "大订单",
                    "盈利预期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "平安证券维持凯莱英强烈推荐评级：再签大订单，提高未来盈利预期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]